Defunct Company
Total Trials
8
As Lead Sponsor
2
As Collaborator
6
Total Enrollment
6,553
NCT04411628
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
Phase: Phase 1
Role: Collaborator
Start: May 28, 2020
Completion: Aug 26, 2020
NCT04427501
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
Phase: Phase 2/3
Start: Jun 17, 2020
Completion: Feb 21, 2023
NCT04497987
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
Phase: Phase 3
Start: Aug 2, 2020
Completion: May 20, 2021
NCT04634409
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Phase: Phase 2
Start: Oct 29, 2020
Completion: Oct 18, 2021
NCT04701658
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Start: Feb 1, 2021
Completion: Jun 22, 2021
NCT07118891
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
Role: Lead Sponsor
Start: Jun 23, 2025
Completion: Feb 28, 2027
NCT07108894
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
Phase: Early Phase 1
Start: Jul 25, 2025
Completion: Nov 30, 2026